Frederick L. Locke, MD
Chimeric antigen receptor (CAR) T-cell therapy has shown durable responses in patients with subtypes of non-Hodgkin lymphoma; however, the key to optimizing responses is early referral, said Frederick L. Locke, MD.
State of the Science Summit™ on Hematologic Malignancies, Locke, one of the lead authors of ZUMA-1, discussed the expansion of CAR T-cell therapy in patients with lymphomas following the 2017 approval of axi-cel and remaining research questions with the therapy.
OncLive: You have been involved in the trials with axi-cel. What is it like to see its FDA approval?
: We now have 2 FDA-approved CAR T-cell products for the treatment of adult [patients with] aggressive B-cell lymphomas. It's been fantastic. We knew from single-center trials that tested CD19-directed CAR T-cell therapy that it could work for patients with B-cell malignancies. As we were running the phase I and then phase II ZUMA-I trial, we saw the greater than 80% response rate in patients who had very little chance for response or complete response. Those responses are durable. Over 40% of patients remain in remission 1 year out with almost a 1.5-year median follow-up. The results have been remarkable.
... to read the full story